Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses
about
Challenges in mucosal HIV vaccine development: lessons from non-human primate modelsPhase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginallyEffect of vaginal immunization with HIVgp140 and HSP70 on HIV-1 replication and innate and T cell adaptive immunity in women.Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulationIntravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage formsNon-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.Sustained release of proteins from a modified vaginal ring device.Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses.Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations.Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines.Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application.Assessment of mucosal immunity to HIV-1.Vaginal gel drug delivery systems: understanding rheological characteristics and performance.Vaginal mucoadhesive drug delivery systems.Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration.Intravaginal flux controlled pump for sustained release of macromolecules.Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans.
P2860
Q27022152-B4A50596-B3BB-4F12-9FD9-A3CDCD93335FQ34044915-39563DC9-6248-4EBF-87A3-DFCC1D8EBF62Q34261593-D6B18022-FC20-4700-B834-62F0471817F5Q34694812-89CAE469-EEB7-4958-9CB6-46F5CEC85E8FQ35061979-003452EB-0518-49D3-AD35-F11272147997Q35563416-A859C2D4-656B-4BFE-89C8-29BDA56069B8Q35940685-6B15367C-CDAC-4C18-9634-26CE381AC8D5Q37143743-EF6CCCE4-CDE4-49A9-BE6E-E64638B94459Q37143750-47E92426-6ACB-467A-8F91-E2633BA467B8Q37187433-80B5E831-BA04-43D2-A688-00C490DEED1DQ37679436-9FE4D1A6-EFB6-4236-8D4D-A8FF77E6C026Q37688254-86D439E5-B206-4B7E-9E41-920C0E073C61Q37724856-D1360AFF-733B-4E7B-A2C5-401F70B137A5Q37897568-BA8A1937-6A10-49E4-9DC1-3F6A4D6F4426Q37945742-591A2F89-3C2E-4D48-96AA-A8EC5C587792Q38636239-59D6CFEA-FA32-4659-AFE6-402CF331A321Q50850632-14187051-81AE-4F1D-B6C9-1445EEE4B573Q52657155-F0D8FCAF-9EBE-48A8-A921-9AF526CE78FF
P2860
Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Vaginal delivery of the recomb ...... cits specific immune responses
@ast
Vaginal delivery of the recomb ...... cits specific immune responses
@en
type
label
Vaginal delivery of the recomb ...... cits specific immune responses
@ast
Vaginal delivery of the recomb ...... cits specific immune responses
@en
prefLabel
Vaginal delivery of the recomb ...... cits specific immune responses
@ast
Vaginal delivery of the recomb ...... cits specific immune responses
@en
P2093
P2860
P1433
P1476
Vaginal delivery of the recomb ...... cits specific immune responses
@en
P2093
A David Woolfson
Carol Fraser
Gavin Andrews
Louise Donnelly
Martin Cranage
R Karl Malcolm
Rhonda M Curran
Ryan J Morrow
P2860
P304
P356
10.1016/J.VACCINE.2009.08.088
P407
P577
2009-09-10T00:00:00Z